567 related articles for article (PubMed ID: 25201455)
1. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
4. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
Bouchard C; Labrie F; Archer DF; Portman DJ; Koltun W; Elfassi É; Grainger DA; Ayotte N; Cooper TA; Martens M; Waldbaum AS; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
Climacteric; 2015; 18(4):590-607. PubMed ID: 25511551
[TBL] [Abstract][Full Text] [Related]
5. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
Panjari M; Davis SR
Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
[TBL] [Abstract][Full Text] [Related]
6. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
7. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial.
Lima SM; Bernardo BF; Yamada SS; Reis BF; da Silva GM; Galvão MA
Maturitas; 2014 Jul; 78(3):205-11. PubMed ID: 24856055
[TBL] [Abstract][Full Text] [Related]
8. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
Montesino M; Labrie F; Archer DF; Zerhouni J; Côté I; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Moyneur E; Balser J
Gynecol Endocrinol; 2016; 32(3):240-5. PubMed ID: 26634942
[TBL] [Abstract][Full Text] [Related]
10. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
[TBL] [Abstract][Full Text] [Related]
11. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
14. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
Wang J; Wang L
Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
[TBL] [Abstract][Full Text] [Related]
16. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Gilbert L; Martel C; Balser J
J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
19. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Martel C; Balser J
Gynecol Endocrinol; 2010 Jul; 26(7):524-32. PubMed ID: 20459349
[TBL] [Abstract][Full Text] [Related]
20. Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient?
Kearley-Shiers K; Holloway D; Janice Rymer ; Bruce D
Post Reprod Health; 2022 Dec; 28(4):237-243. PubMed ID: 36300276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]